Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1997 1
1998 1
1999 2
2000 3
2003 1
2005 1
2006 1
2008 1
2010 1
2011 3
2013 2
2014 3
2015 3
2016 5
2017 2
2018 2
2019 4
2020 8
2021 8
2022 5
2023 9
2024 8
2025 22

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
Cognitive disorders in patients with chronic kidney disease: Approaches to prevention and treatment.
Pépin M, Klimkowicz-Mrowiec A, Godefroy O, Delgado P, Carriazo S, Ferreira AC, Golenia A, Malyszko J, Grodzicki T, Giannakou K, Paolisso G, Barbieri M, Garneata L, Mocanu CA, Liabeuf S, Spasovski G, Zoccali C, Bruchfeld A, Farinha A, Arici M, Capasso G, Wiecek A, Massy ZA; CONNECT (Cognitive Decline in Nephro-Neurology: European Cooperative Target) Action. Pépin M, et al. Among authors: farinha a. Eur J Neurol. 2023 Sep;30(9):2899-2911. doi: 10.1111/ene.15928. Epub 2023 Jun 29. Eur J Neurol. 2023. PMID: 37326125 Free article. Review.
Cognitive impairment in CKD patients: a guidance document by the CONNECT network.
Bolignano D, Simeoni M, Hafez G, Pepin M, Gallo A, Altieri M, Liabeuf S, Giannakou K, De A, Capasso G; CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target) collaborators. Bolignano D, et al. Clin Kidney J. 2024 Sep 30;18(2):sfae294. doi: 10.1093/ckj/sfae294. eCollection 2025 Feb. Clin Kidney J. 2024. PMID: 40235626 Free PMC article. Review.
Chemotherapy-related cognitive impairment and kidney dysfunction.
Simeoni M, Mulholland MM, Workeneh BT, Capasso A, Hafez G, Liabeuf S, Malyszko J, Mani LY, Trevisani F, De A, Wagner CA, Massy ZA, Unwin R, Capasso G; CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target) collaborators. Simeoni M, et al. Nephrol Dial Transplant. 2025 Mar 13;40(Supplement_2):ii54-ii63. doi: 10.1093/ndt/gfae249. Nephrol Dial Transplant. 2025. PMID: 40080088 Free PMC article. Review.
Cognitive impairment in kidney transplanted patients.
Malyszko J, Golenia A, Farisco M, Re VL, Klimkowicz-Mrowiec A, Capasso G, Goumenos D, Rroji M, Figurek A, Hafez G; CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target) collaborators. Malyszko J, et al. Nephrol Dial Transplant. 2025 Mar 13;40(Supplement_2):ii46-ii53. doi: 10.1093/ndt/gfae250. Nephrol Dial Transplant. 2025. PMID: 40080090 Free PMC article. Review.
Drugs with a negative impact on cognitive function (Part 1): chronic kidney disease as a risk factor.
Liabeuf S, Pešić V, Spasovski G, Maciulaitis R, Bobot M, Farinha A, Wagner CA, Unwin RJ, Capasso G, Bumblyte IA, Hafez G; CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target). Liabeuf S, et al. Among authors: farinha a. Clin Kidney J. 2023 Sep 18;16(12):2365-2377. doi: 10.1093/ckj/sfad241. eCollection 2023 Dec. Clin Kidney J. 2023. PMID: 38045996 Free PMC article. Review.
Genetic and circulating biomarkers of cognitive dysfunction and dementia in CKD.
Zoccali C, Mallamaci F, Wagner CA, Unwin R, Nedergaard M, Hafez G, Malyszko J, Pepin M, Massy Z, Paolisso G, Remuzzi G, Capasso GB; CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target) collaborators. Zoccali C, et al. Nephrol Dial Transplant. 2025 Mar 13;40(Supplement_2):ii64-ii75. doi: 10.1093/ndt/gfae259. Nephrol Dial Transplant. 2025. PMID: 40080085 Free PMC article. Review.
89 results